This study is a Phase 2 multicenter study with a Safety Lead-in evaluating safety and efficacy of MT-401 administration to patients with AML, who have received their first allogeneic HSCT. The dose administered is 50 x 10^6 cells (flat dosing).
Recruiting
Phase 2
| Drug | Synonyms | Arms |
|---|---|---|
| MT-401 | zelenoleucel | MT-401 following HSCT |
This study is in patients aged ≥18 years old undergoing or having relapsed after their first
allogeneic HSCT (matched sibling, matched unrelated donor, or haploidentical transplants) for
AML.
Potential patients for the study may be screened/enrolled:
• Prior to their first allogeneic HSCT.
or
• Patients experiencing their first relapse post-allogeneic transplant.
Patients eligible for the study will be placed into one of two groups:
- Adjuvant (Group 1): Patients screened prior to their HSCT with CR without minimal
residual disease (CRMRD-) at 90 days post transplant will be randomized (1:1) in an
unblinded fashion to:
- MT-401 (Arm A)
- SOC (Arm B)
- Active Disease: (Group 2): Patients meeting the following criteria will be assigned to
Group 2 and will receive MT 401:
- Patients who experience relapse (patients with MRD [MRD+] or frank relapse) at or
prior to post-transplant Day 90
- Patients in Arm B of Group 1 (SOC) who develop relapse (MRD+ or frank relapse)
post-HSCT (crossover patients)
- Patients who do not consent prior to HSCT but are experiencing their first relapse
(MRD+ or frank relapse) and have the same donor available for manufacturing
| Name | Type | Description | Interventions |
|---|---|---|---|
| MT-401 following HSCT | Experimental | Treatment with MT-401 at 90 days following HSCT |
|
| Standard of Care following HSCT | No Intervention | Standard of Care | |
| MT-401 following relapse | Experimental | Treatment with MT-401 following relapse after first HSCT |
|
Inclusion Criteria
1. First allogeneic HSCT, in ≤ CR2, and MRD negative prior to transplant (including
matched sibling, MUD with at least 6 of 8 HLA markers, or haploidentical with at least
5 of 10 HLA markers) as:
- Adjuvant therapy for AML (Group 1) at 90 days (±10 days) post-HSCT defined as
patients with CRMRD; or
- Treatment for refractory/relapsed AML (first relapse post-HSCT) when disease
occurs after transplant (Group 2) defined as
- First relapse (MRD+ or frank relapse) post-HSCT
- Patients in Arm 1B (SOC) who experience first relapse (MRD+ or frank
relapse) post HSCT
- Safety Lead-in defined as patients who fit all the criteria for Group 2 only
2. Are ≥18 years of age
3. Karnofsky/Lansky score of ≥60
4. Life expectancy ≥12 weeks
5. Adequate blood, liver, and renal function
- Blood: Hemoglobin ≥7.0 g/dL (can be transfused)
- Liver: Bilirubin ≤2X upper limit of normal; aspartate aminotransferase ≤3X upper
limit of normal
- Renal: Serum creatinine ≤2X upper limit of normal or measured or calculated
creatinine clearance ≥45mL/min
7. Patients are allowed to be on experimental conditioning regimens prior to transplant if
no planned maintenance therapy post-transplant.
8. In Group 2, patients may receive bridging therapy at the investigators' discretion in
situations where MT-401 is not ready for administration or the treating physician believes
the patient would benefit
Exclusion Criteria
1. Clinically significant or severely symptomatic intercurrent infection
2. Pregnant or lactating
3. For Group 1, anti-neoplastic therapy after HSCT and prior to or during dosing of
MT-401
4. For Group 2, concomitant anti-neoplastic therapy during or after dosing of MT-401
5. Evidence of acute or chronic GVHD ≥Grade 2 (exception: acute or chronic Grade 2 GVHD
of skin allowed if stable) within one week prior to receiving MT-401
| Maximum Eligible Age: | N/A |
| Minimum Eligible Age: | 18 Years |
| Eligible Gender: | All |
| Healthy Volunteers: | No |
| Measure: | Safety Lead-In |
| Time Frame: | Baseline through Cycle 1 (28 Days) |
| Safety Issue: | |
| Description: | Number of participants with MT-401 Dose Limiting Toxicities (DLTs) |
| Phase: | Phase 2 |
| Primary Purpose: | Interventional |
| Overall Status: | Recruiting |
| Lead Sponsor: | Marker Therapeutics, Inc. |
July 19, 2021
